A Clinical Study to Evaluate an Experimental Universal Influenza Vaccine, INFLUENZA G1 mHA, in Healthy Adults

Phase 1/2 Completed 170 enrolled Janssen Vaccines & Prevention B.V. Biomedical Advanced Research and Development Authority · collab

RandomizedSequentialDouble-blindPrevention

Summary

The primary purpose of this study is to evaluate safety/ reactogenicity of INFLUENZA G1 mini-hemagglutinin stem-derived protein vaccine antigen (mHA), with or without Al(OH)3 adjuvant, in healthy adults greater than or equal to (\>=) 18 to less than or equal to (\<=) 45 years of age.

Timeline

Start: 2023-05-17
Primary completion: 2024-08-19
Completion: 2024-08-19

Publications

Hertoghs N, Tang C, van Paassen V, Jongeneelen M, Tolboom J, Yieh L, Wang M, Kaszas K, McLean C, van den Berg S, Lowson D, Hu W, Aguilar Z, Hendriks J, Kuipers H, Kulke S, Sadoff J, Brandenburg B, Zahn R. A group 1 hemagglutinin stem vaccine elicits broad humoral responses against influenza in phase 1/2a study. Nat Commun. 2026 Apr 13;17(1):3451. doi: 10.1038/s41467-026-70396-1.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	INFLUENZA G1 mHA	Vaccine	45 ug	Intramuscular
Subject	INFLUENZA G1 mHA	Vaccine	135 ug	Intramuscular
Background	Al(OH)3	Unknown	—	Intramuscular

Indications

No indication recorded.